<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The feasibility and efficacy of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (CODOX-M)/ifosfamide, <z:chebi fb="0" ids="4911">etoposide</z:chebi>, and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (IVAC) therapy in Japanese adult patients with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, unclassifiable, with features intermediate between diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> (intermediate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) have never been reported </plain></SENT>
<SENT sid="1" pm="."><plain>The effects of adding rituximab to CODOX-M/IVAC have not been published either </plain></SENT>
<SENT sid="2" pm="."><plain>Fifteen consecutive patients with a median age of 39 years were treated with modified CODOX-M/IVAC regimen (particularly, reducing the dose of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> to 3 g/m(2)) with or without rituximab at our institution </plain></SENT>
<SENT sid="3" pm="."><plain>Although <z:hpo ids='HP_0000001'>all</z:hpo> patients developed grade 4 <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and grade 3/4 <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>/<z:hpo ids='HP_0001903'>anemia</z:hpo>, 93% had febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, 60% showed transaminase elevation, and 40% had mucositis/<z:hpo ids='HP_0010280'>stomatitis</z:hpo> (<z:hpo ids='HP_0000001'>all</z:hpo> grade 3), there were no treatment-related <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Two of nine patients treated with rituximab developed biphasic <z:hpo ids='HP_0003584'>late-onset</z:hpo> <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Thirteen patients (87%) showed complete responses </plain></SENT>
<SENT sid="6" pm="."><plain>The remaining two patients had refractory disease; one had presented with peritoneal dissemination and complex chromosomal abnormalities, while the other had double IGH-MYC and IGH-BCL2 translocations </plain></SENT>
<SENT sid="7" pm="."><plain>The estimated 5-year overall and progression-free survival were 87% each, with a median follow-up of 74 months </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, our modified CODOX-M/IVAC regimen is well tolerated and highly effective in Japanese adult patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and intermediate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, warranting a larger study for confirmation </plain></SENT>
</text></document>